पदोन्नति कार्यक्रम Genelux Corporation
उन्नत शेड्यूल
सरल ग्राफ
कंपनी के बारे में Genelux Corporation
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. अधिक जानकारीIPO date | 2023-01-26 |
---|---|
ISIN | US36870H1032 |
Industry | Biotechnology |
Sector | Health Care |
Валюта | usd |
Валюта отчета | usd |
Сайт | https://www.genelux.com |
Цена ао | 5.95 |
प्रति दिन मूल्य परिवर्तन: | +0.813% (2.46) |
---|---|
प्रति सप्ताह मूल्य परिवर्तन: | +9.25% (2.27) |
प्रति माह मूल्य परिवर्तन: | -7.81% (2.69) |
3 महीने में कीमत में बदलाव: | +14.29% (2.17) |
छह महीने में कीमत में बदलाव: | +45.03% (1.71) |
प्रति वर्ष मूल्य परिवर्तन: | -82.3% (14.01) |
3 वर्षों में मूल्य परिवर्तन: | 0% (2.48) |
5 वर्षों में मूल्य परिवर्तन: | 0% (2.48) |
10 वर्षों में मूल्य परिवर्तन: | 0% (2.48) |
वर्ष की शुरुआत से मूल्य परिवर्तन: | -22.74% (3.21) |
|
बहुत मूल्यवान समझना
|
क्षमता
|
|||||||||||||||||||||||||||||||||||||
लाभांश
|
कर्तव्य
|
विकास का आवेग
|
संस्थानों | आयतन | शेयर करना, % |
---|---|---|
Blackrock Inc. | 1196123 | 4.48 |
Vanguard Group Inc | 980993 | 3.67 |
Geode Capital Management, LLC | 386634 | 1.45 |
State Street Corporation | 231065 | 0.86 |
AE Wealth Management LLC | 194875 | 0.73 |
Northern Trust Corporation | 160816 | 0.6 |
Provident Wealth Management, LLC | 157137 | 0.59 |
Charles Schwab Investment Management, Inc. | 149604 | 0.56 |
Bank Of New York Mellon Corporation | 53841 | 0.2 |
AMG National Trust Bank | 50346 | 0.19 |
ETF | शेयर करना, % | वर्ष के लिए लाभप्रदता, % | लाभांश, % |
---|---|---|---|
Range Cancer Therapeutics ETF | 0.53743 | 47.24 | 0.11955 |
iShares Micro-Cap ETF | 0.01521 | 17.09 | 1.54048 |
![]() |
0.0013 | 17.47 | 1.51433 |
0.19 | 27.27 | 1.06 |
पर्यवेक्षक | नौकरी का शीर्षक | भुगतान | जन्म का साल |
---|---|---|---|
Mr. Thomas Zindrick J.D. | Chairman, CEO & President | 570.99k | 1959 (66 साल) |
Mr. Sean Ryder J.D. | General Counsel & Corporate Secretary | 380k | 1969 (56 साल) |
Ms. Lourie S. Zak | Chief Financial Officer | 346.19k | 1963 (62 वर्ष) |
Dr. Joseph Cappello Ph.D. | Chief Technical Officer | 213.08k | 1957 (68 साल) |
Dr. Yong Yu Ph.D. | Senior Vice President of Clinical Development | 242.62k | 1971 (54 वर्ष) |
Prof. Paul Scigalla M.D., Ph.D. | Chief Medical Officer | N/A | 1945 (80 साल) |
Mr. Ralph Smalling B.Sc. | VP & Head of Regulatory Affairs | N/A | 1957 (68 साल) |
Ms. Caroline Jewett | VP & Head of Quality | 269.26k | 1965 (60 साल) |
पता: United States, Westlake Village. CA, 2625 Townsgate Road - Google मानचित्र में खोलें, यांडेक्स मानचित्र खोलें
वेबसाइट: https://www.genelux.com
वेबसाइट: https://www.genelux.com